Galafold (migalastat) — Medica
Fabry disease
Initial criteria
- Patient is age ≥ 18 years
- Patient has an amenable galactosidase alpha gene (GLA) variant based on in vitro assay data
- Medication is prescribed by or in consultation with a geneticist, nephrologist, or a physician who specializes in the treatment of Fabry disease
Approval duration
1 year